Article Text

Download PDFPDF
Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ZH reports receiving lecture fees from Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Roche Diagnostics; consulting fees from Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer, and Roche Diagnostics. LW: institutional research grants, consultancy and lecture fees, and travel support from AstraZeneca, BMS and Pfizer, Boehringer Ingelheim, and GlaxoSmithKline; honoraria from GlaxoSmithKline; institutional research grant from Merck & Co. and Roche; consultancy fees from Abbot; holds two patents involving GDF-15.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Arrhythmias and sudden death
    Taku Inohara Sunghee Kim Karen Pieper Rosalia G Blanco Larry A Allen Gregg C Fonarow Bernard J Gersh Michael D Ezekowitz Peter R Kowey James A Reiffel Gerald V Naccarelli Paul S Chan Kenneth W Mahaffey Daniel E Singer James V Freeman Benjamin A Steinberg Eric D Peterson Jonathan P Piccini